TY - JOUR AU - Kalra, Maitri AU - Nakshatri, Harikrishna PY - 2017 TI - Will PI3K-targeted therapies for cancer become a reality? JF - Translational Cancer Research; Vol 6, Supplement 2 (March 31, 2017): Translational Cancer Research Y2 - 2017 KW - N2 - In a recent issue of Annals of Oncology , Vuylsteke and colleagues presented the interim analysis of phase II PEGGY study on the use of pictilisib [a pan-phosphoinositide-3-kinase (PI3K) inhibitor] plus paclitaxel in hormone receptor positive human epidermal receptor 2 (HER2) negative (ER+/HER2−) locally advanced or metastatic breast cancer (1). This clinical trial is one among the many clinical clinicals to report clinical benefits and toxicity associated with PI3K-targeted therapies. UR - https://tcr.amegroups.org/article/view/12678